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Abstract
Introduction: Chlamydia and gonorrhea are the most commonly reported notifiable infections in 
the U.S., with direct medical costs for the treatment of these infections exceeding $700 million 
annually. Medicaid currently covers approximately 80 million low-income Americans, including a 
high percentage of racial and ethnic minorities. Studies have shown that racial and ethnic minority 
populations, particularly those with low SES, are at an increased risk of acquiring a sexually 
transmitted disease. Therefore, as Medicaid expands, there will likely be a greater demand for 
sexually transmitted disease services in community-based physician offices. To determine demand 
for these services among Medicaid enrollees, this study examined how often Medicaid was used to 
pay for sexually transmitted disease services received in this setting.
Methods: This study combined 2014 and 2015 data from the National Ambulatory Medical Care 
Survey and tested for differences in the proportion of visits with an expected payment source of 
Medicaid when sexually transmitted disease services were and were not provided. All analyses 
were conducted in October 2018.
Results: During 2014–2015, an estimated 25 million visits received a sexually transmitted 
disease service. Medicaid paid for a greater percentage of sexually transmitted disease visits 
(35.5%, 95% CI=22.5%, 51.1%) compared with non–sexually transmitted disease visits (12.1%, 
95% CI=10.8%, 13.6%). Logistic regression modeling, controlling for age, sex, and race of the 
patient, showed that visits covered by Medicaid had increased odds of paying for a sexually 
transmitted disease service visit (OR=1.97, 95% CI=1.12, 3.46), compared with other expected 
payment sources.
Conclusions: Focusing sexually transmitted disease prevention in Medicaid populations could 
reduce sexually transmitted disease incidence and resulting morbidity and costs.
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INTRODUCTION
With a combined total of more than 2 million reported cases in 2016, chlamydia and 
gonorrhea are the most commonly reported notifiable diseases in the U.S.1 The latest 
surveillance data indicate that the incidence of these infections is rising sharply,2 and direct 
medical costs for the treatment of these infections total nearly $700 million per year.3
Previous work has determined that people who are from racial and ethnic minority 
populations or who have relatively low SES are considered to be at greater risk of acquiring 
sexually transmitted diseases (STDs) compared with people who are not from racial and 
ethnic minority populations and those who have relatively higher SES measures.4 Successful 
interventions and reductions in national STD rates are difficult due in part to the frequently 
asymptomatic nature of both infections, with the majority of infected individuals unaware of 
their status.2 Screening strategies that are based on population or behavioral risk profiles 
have thus been developed (e.g., females under age 26 years and men who have sex with 
men). Still, many who are at risk do not receive recommended screening.5 As the U.S. 
grapples with both increasing rates of STDs and the specter of antimicrobial-resistant 
gonorrhea,6 it may be useful to examine means to increase the efficiency and efficacy of 
existing screening paradigms.
STD screening occurs primarily in public or private clinical settings, and the majority of 
cases have been identified through primary and emergency care venues,2,7 and there are 
trends demonstrating decreasing numbers of bacterial STDs being reported by STD clinics.8 
Alternatively, publicly funded safety-net STD clinics and screening services provided by 
local health departments have traditionally been important to prevention efforts by serving 
medically underserved subpopulations who may lack insurance or ready access to quality 
clinical care.9 Unfortunately, public health systems generally, and STD clinics and local 
health department–provided STD screening services specifically, are currently experiencing 
reduced funding and subsequent reduced capacity.10–12 It is possible that recent healthcare 
system changes have affected the financing and delivery of STD care, particularly in public 
clinics and among populations at increased risk for STDs.13,14
Currently, Medicaid covers more than 70 million low-income Americans, including a high 
percentage of racial and ethnic minorities, and accounts for 16% of all healthcare spending 
in the U.S.15 Furthermore, since the passing of the Affordable Care Act, Medicaid rolls have 
grown by approximately 30%,16 and among people who are Medicaid recipients, 
approximately 80% receive their care through a managed care plan, which allows for 
patients to receive care in community-based physician offices.17 These circumstances 
suggest that there is greater demand being placed on publicly funded health care, and this 
health care is increasingly being delivered through public/private partnerships, such as 
private insurance companies contracting with Medicaid to provide health services to 
Medicaid enrollees in community-based physician offices. Therefore, because of the 
growing role of Medicaid in funding health services, and the increased likelihood of STDs 
being diagnosed in populations covered by Medicaid, these analyses seek to determine the 
extent to which Medicaid is used to pay for STD care in community-based physician offices.
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METHODS
Study Sample
Data for these analyses were taken from the most recently available ambulatory care data 
released by the National Center for Health Statistics. Two years (2014 and 2015) of data 
from the National Ambulatory Medical Care Survey were combined for these analyses in 
order to ensure a large enough sample size of visits that had an associated STD service. The 
National Ambulatory Medical Care Survey is a publicly available, nationally representative 
survey of visits to non-federally employed, office-based physicians in the U.S. This sample 
excludes physicians practicing in hospitals, emergency departments, and federally funded 
clinics, such as federally qualified health centers (FQHCs), and offices that serve primarily 
U.S. Veteran populations.18
Measures
All 74,042 sampled visits were stratified by expected payment source, including private 
insurance, Medicare, Medicaid/State Children’s Health Insurance Plan (SCHIP), and all 
other payer types, and provided weighted estimates of the total number of visits made for 
each expected payment source. Demographic estimates were provided for each expected 
payment source, including mean age of the patients making the visits, percentage of visits 
made by females, and percentage of visits made by non-Hispanic white individuals, in order 
to provide an overall description of the population.
All visit records were searched for indication of an STD service being provided at the visit. 
The criteria used to identify these visits as having an associated STD service included a 
diagnosis of chlamydia, gonorrhea, or unspecified venereal disease; a chlamydia or 
gonorrhea test being performed; or STD counseling being provided at the visit. Using these 
criteria, a total of 732 unweighted visits were classified as having an associated STD service.
Statistical Analysis
These visits were stratified by mean age of the patients making the visits, percentage of 
visits made by females, percentage of visits made by non-Hispanic white patients, and 
percentage of visits where Medicaid/SCHIP was the expected payment source. Differences 
in proportions were tested using a t-test for mean age and chi-square tests for percentage of 
visits made by females and non-Hispanic whites. Logistic regression analysis was then used 
to calculate the odds of having Medicaid/SCHIP as the expected payment source for the 
STD visit, while taking into account the age (defined as <40 years versus ≥40 years), sex 
(male versus female), and race (white versus non-white) of the patient. SUDAAN, version 
11.0, was used for all analyses in order to take into account the complex sampling design of 
the surveys and to apply national weights to the estimates. All analyses occurred in October 
2018.
RESULTS
Over the 2-year period of 2014 to 2015, there were nearly 1.9 billion office visits made to 
community-based physicians in the U.S. Private insurance was the expected payment source 
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for approximately 48% of these visits. Medicare accounted for approximately 27% of these 
visits. Medicaid/SCHIP accounted for an estimated 12.4% of these visits and all other 
expected payment sources accounted for an estimated 12.3% of these visits. Among visits 
where Medicaid/SCHIP was the expected payment source, patients were typically younger, 
with a mean age of 27.7 years, and more racially diverse, with an estimated 46.0% of visits 
made by non-Hispanic white patients, compared with all other expected payment sources. 
The percentage of visits made by females was not significantly different among the expected 
payment sources and ranged from an estimated 56.9% for visits where Medicare was the 
expected payment source, up to an estimated 62.4% of visits where Medicaid/SCHIP was 
the expected payment source (Table 1).
After stratifying by STD service, of all visits, approximately 25 million (1.3%) had an 
associated STD service provided at the time of the visit. The mean age of patients attending 
visits for STD services was significantly younger compared with all other visits (31.6 vs 
48.6 years, p<0.05). A significantly greater percentage of the STD service visits were made 
by females compared with all other visits (76.8% vs 58.1%, p<0.05). Patients who were non-
Hispanic white were a significantly smaller percentage of STD service visits compared with 
all other visits (41.9% vs 68.8%, p<0.05). The percentage of visits paid for by Medicaid/
SCHIP was significantly higher for STD service visits compared with all other visits (35.5% 
vs 12.1%, p<0.01; Table 2).
Unadjusted logistic regression models demonstrated that visits with Medicaid/SCHIP as the 
expected payment source had nearly four times the odds of having an STD service visit 
compared with all other payment sources (OR=3.99, 95% CI=2.19, 7.25). After controlling 
for patients’ age, sex, and race, visits covered by Medicaid/SCHIP still had nearly twice the 
odds of having an STD service visit compared with all other payment sources (OR=1.97, 
95% CI=1.12, 3.46; Table 3).
DISCUSSION
These findings suggest that Medicaid disproportionately covers services for STDs compared 
with other payment sources. This disproportionate payment for STD services most likely 
reflects the composition of Medicaid populations as being those more likely to require STD 
care: typically younger and having a greater proportion of minorities and females. Therefore, 
focusing efforts for STD prevention in Medicaid populations may be worthwhile.
Currently, the majority of Medicaid beneficiaries receive health services through MCOs,16,17 
which may be the reason for more Medicaid services being delivered in private physician 
offices than has traditionally been the case. Furthermore, studies looking into utilization of 
healthcare services after Medicaid expansion have shown that states that have expanded their 
Medicaid programs have also seen overall increased use of health services.19 Therefore, 
because of increases in the number of Medicaid-eligible individuals, as well as increases in 
Medicaid managed care, it is possible that more people are seeking STD care in private 
physician offices, especially in states where Medicaid expansion has occurred. Stakeholders 
and policymakers should monitor the STD prevention implications of these significant shifts 
in Medicaid enrollment and administration.
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Previous work examining the effects of managed care models on delivering STD services to 
Medicaid populations suggest that several barriers exist to providing quality STD services, 
including low-reimbursement rates for high-cost services, as well as a lack of understanding 
of the downstream costs of untreated STDs.20 Further work in this area has suggested that in 
order to curb STD infections, the structuring of contracts between providers and MCOs 
should focus more on reimbursement for quality of care as opposed to volume of care.21,22
More recent research found that STD testing rates among a Medicaid-insured, HIV-positive 
population were as low as 20% across 20 states, suggesting that Medicaid recipients are not 
receiving optimal care because this is a population for which engagement with the 
healthcare system should be higher than in the general population.23 Various payment 
reforms have been implemented in order to address quality of care issues such as this. One 
such program by the Centers for Medicare and Medicaid Services, called the Delivery 
System Reform Incentive Payment, provides payments to safety-net hospitals providing care 
to large Medicaid populations, with the funds being tied to providers meeting performance 
metrics (i.e., pay for performance).24 Delivery System Reform Incentive Payment also 
includes patient-level measures, such as establishing medical homes for patients, as well as 
expanding ambulatory clinic hours and increasing incentive payments to physician 
providers.25,26 More generally, pay for performance, which has been a trend in healthcare 
financing for more than a decade, is merely one form of payment reform that has been 
proposed or is being implemented currently across the U.S., with the goal of improving 
quality and resource efficiency. Other alternatives include bundled payments, accountable 
care organizations, and capitation. It is hoped that programs such as this will increase the 
quality of all services provided to Medicaid recipients, including STD services.
However, even with Medicaid expansion, traditional STD clinics are still experiencing 
demand for services. A survey conducted in 2013 at 21 STD clinics around the U.S. found 
that nearly half of all patients seeking care in the clinics were uninsured.27 Additionally, it 
was found that among the patients seeking care in those clinics who did have health 
insurance, about half were willing to use their insurance for their care, but others were not 
due to privacy and out-of-pocket costs.28 Even in states with notable Medicaid expansion, 
many people still sought care in STD clinics because of being uninsured.29,30 Therefore, it 
appears that STD clinics will remain as a source of care for people who are either uninsured 
or who are unwilling to use their insurance for STD care. Even so, as mentioned previously, 
STD clinics are beginning to bill for Medicaid services in order to cover their costs.14 
Because of this, researchers may wish to investigate whether patients seeking care in STD 
clinics receive comparable care to those who seek STD care in community-based physician 
offices. Stake-holders should monitor U.S. healthcare system reforms, including 
amendments to the eligibility standards of Medicaid (or other public programs), in a way 
that broadens the program to additional populations, for how they affect the rate of people 
being uninsured, and ultimately, access to STD services.
Alternatively, although patients may still seek care for STDs outside of private physician 
offices, Medicaid remains an important payer in settings such as FQHCs and STD clinics. 
Medicaid has been determined to be a significant payer for FQHCs and an issue brief put out 
by the Medicaid and CHIP Payment and Access Commission noted that Medicaid is the 
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largest source of revenue for FQHCs and that nearly half of FQHC patients were also 
Medicaid beneficiaries.31 Relatedly, a study conducted in 2017 at 56 local health 
departments in North Carolina found that 95% of the surveyed clinics were billing Medicaid 
for services.32 For studies conducted specifically in STD clinics, Medicaid was determined 
to be a significant source of revenue. One of these studies conducted in the early 2000s in 
King County, Washington noted that nearly 31% of one clinic’s revenue was derived from 
Medicaid,33 and a more recent study conducted in 2017 at a publicly funded STD clinic in 
Rhode Island found that Medicaid was an important source of revenue and could possibly 
even support clinic operations when some patients remain uninsured.34 Therefore, focusing 
STD prevention efforts toward Medicaid populations, even when seeking care in other 
venues, can be beneficial.
Limitations
There are several limitations that should be considered when interpreting these results. First, 
the STD service was defined using ICD codes and data set variables indicating chlamydia/
gonorrhea test performance and STD counseling provision during the visit. This survey data 
do not allow the use of Current Procedural Terminology codes, perhaps underestimating the 
total STD services provided. Second, the authors were not able to determine whether a 
Medicaid enrollee was also enrolled in a Medicaid managed care plan. Managed care may 
offer improvements in quality of care compared with people receiving care that is paid for 
strictly through a fee-for-service arrangement. Third, expected payment source was used as 
the outcome of interest and these data are based on claims that are not adjudicated, meaning 
that it was not possible to determine which insurer actually paid for the claim.
CONCLUSIONS
Population groups historically at increased risk of STD infection (lower income, minority 
race, and younger age) and associated morbidity (female sex) are disproportionately 
represented among Medicaid/SCHIP enrollees. The increasing utilization of Medicaid/
SCHIP as an insurer may have implications for STD prevention efforts nationally, and 
specifically for populations at increased infection risk. Simply providing health insurance 
through Medicaid does not necessarily ensure access to high-quality STD services. 
Therefore, in order to ensure sexual health at a larger population level, it may be beneficial 
to communicate the necessity of STD prevention to programs that are charged with caring 
for vulnerable populations, such as Medicaid. Additionally, as the healthcare landscape 
continues to evolve, including moving more Medicaid and SCHIP care to managed care 
environments, it is important to monitor the scope of services covered by publicly funded 
health insurance programs to determine how government funds are being allocated and the 
quality of care received.
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